Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

WTAS: Inflation Reduction Act already impacting R&D decisions

Nicole Longo
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions.

In their own words: Insured Americans support policy reforms that address access and affordability concerns

Tom Wilbur
A survey of more than 5,000 Americans conducted with Ipsos found that insured Americans want better health care coverage.

New data show how insurers and middlemen shift Rx costs onto patients

Brian Newell
There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter.